CliffBio
biologic

Eylea

aflibercept

Loss of exclusivityAugust 2030projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEylea
Active ingredientaflibercept
Strength2MG/0.05ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalAugust 2018
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Eylea patent cliff — loss of exclusivity August 2030 | CliffBio